Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL27600491 | 0.98 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL268199 | 0.87 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2721649 | 0.83 | TSHR (0.55) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL30525281 | 0.83 | VCAM1 (0.64) | GAAPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL559830 | 0.83 | VCAM1 (0.64) | GAAPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL6960199 | 0.83 | KDM4E (0.55) | FLT1KDRTDP1ALDH1A1MEN1 | |
| SCHEMBL2126420 | 0.83 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22749334 | 0.83 | CYP1A2 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1318248 | 0.82 | ABCB1 (0.47) | GAASIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL616603 | 0.82 | GAA (0.63) | GAASIRT6PDGFRBFGFR1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236810-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING BENZENE DERIVATIVES | OSMO LABS, PBC | 2025-07-24 | — | — | US | disclosed |
| US-20230357253-A1 | AGONISTS OF STIMULATOR OF INTERFERON GENES STING | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-09 | — | — | US | disclosed |
| CN-116940567-A | Agonists of the interferon gene stimulator STING | 斯克里普斯研究学院 | 2023-10-24 | — | — | CN | disclosed |
| US-11771694-B2 | Arylamide compounds for treatment and prevention of viral infections | INNOVATION PHARMACEUTICALS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-113004286-B | Tricyclic compounds as plasma kallikrein inhibitors and uses thereof | 成都康弘药业集团股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20210379058-A1 | Arylamide Compounds For Treatment And Prevention Of Viral Infections | INNOVATION PHARMACEUTICALS INC. | 2021-12-09 | — | — | US | disclosed |
| WO-2021121396-A1 | TRICYCLIC COMPOUND THAT ACTS AS PLASMA KALLIKREIN INHIBITOR AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| CN-113004286-A | Tricyclic compounds as plasma kallikrein inhibitors and uses thereof | 成都康弘药业集团股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
| WO-2021037090-A1 | NAPHTHYLAMINE COMPOUND AND BIOLOGICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 河南省锐达医药科技有限公司 | 2021-03-04 | — | — | WO | disclosed |
| WO-2020246487-A1 | COMPOUNDS HAVING DISPIRO DIKETOPIPERAZINE STRUCTURE | 第一三共株式会社 | 2020-12-10 | — | — | WO | disclosed |
| EP-1608313-A2 | FACIALLY AMPHIPHILIC POLYMERS AND OLIGOMERS AND USES THEREOF | The Trustees of The University of Pennsylvania (US) | 2005-12-28 | — | — | EP | disclosed |
| CN-1608053-A | Heterocyclic derivatives of glycinamide and its pharmaceutical uses | SMITHKLINE BEECHAM PLC (GB) | 2005-04-20 | — | — | CN | disclosed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | disclosed |
| US-20050043335-A1 | Such as N-methyl-2-(2-(2-(2,3-difluorophenyl)ethyl)-7-(3-dimethylaminoprop-1-yl)-4-oxo-4H-quinolin-1-yl)-N-(4-(4-trifluoromethylphenyl)benzyl)acetamide bitartrate; plateley activating factor acetylhydrolase inhibitors; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2005-02-24 | — | — | US | disclosed |
| WO-2004082634-A2 | FACIALLY AMPHIPHILIC POLYMERS AND OLIGOMERS AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040185257-A1 | Microbiocide surfaces; contact antiseptic | NSF - DEITR | 2004-09-23 | — | — | US | disclosed |
| EP-1372551-A4 | FACIALLY AMPHIPHILIC POLYMERS AS ANTI-INFECTIVE AGENTS | UNIV PENNSYLVANIA (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1372551-A2 | FACIALLY AMPHIPHILIC POLYMERS AS ANTI-INFECTIVE AGENTS | The University of Pennsylvania (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002100295-A2 | FACIALLY AMPHIPHILIC POLYMERS AS ANTI-INFECTIVE AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070584-A1 | Substituted aryloximes | AHR, NQO1, AOX1 | CA12 1107/4885CA1 3384/4885CA2 2562/4885 |
| US-20210379058-A1 | Arylamide Compounds For Treatment And Prevention Of Viral Infections | HAVCR2, EIF2AK2, IRF3 | CA12 3986/4885CA1 4816/4885CA2 3951/4885 |
| US-20050043335-A1 | Such as N-methyl-2-(2-(2-(2,3-difluorophenyl)ethyl)-7-(3-dimethylaminoprop-1-yl)-4-oxo-4H-quinolin-1-yl)-N-(4-(4-trifluoromethylphenyl)benzyl)acetamide bitartrate; plateley activating factor acetylhydrolase inhibitors; for treatment of atherosclerosis | PLA2G7, PAFAH1B2, PLAAT2 | CA12 4008/4885CA1 2205/4885CA2 1760/4885 |
| US-20250236810-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING BENZENE DERIVATIVES | BBOX1, NISCH, TAS2R4 | CA12 4161/4885CA1 4567/4885CA2 4347/4885 |
| US-20230357253-A1 | AGONISTS OF STIMULATOR OF INTERFERON GENES STING | STING1, IRF3, CGAS | CA12 4850/4885CA1 4880/4885CA2 4518/4885 |
| US-11771694-B2 | Arylamide compounds for treatment and prevention of viral infections | HAVCR2, EIF2AK2, IRF3 | CA12 3986/4885CA1 4816/4885CA2 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.